| Identification | Back Directory | [Name]
(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol | [CAS]
2040291-27-6 | [Synonyms]
LLY-283
LM-5179
LLY-283
(LLY283)
LLY-283 >=98% (HPLC)
7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(5R)-5-C-phenyl-β-D-ribofuranosyl]-
(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol | [Molecular Formula]
C17H18N4O4 | [MDL Number]
MFCD31657362 | [MOL File]
2040291-27-6.mol | [Molecular Weight]
342.35 |
| Chemical Properties | Back Directory | [Boiling point ]
688.9±55.0 °C(Predicted) | [density ]
1?+-.0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 60 mg/ml; Ethanol: 60 mg/ml | [form ]
A crystalline solid | [pka]
12.46±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
LLY-283 is an inhibitor of protein arginine methyltransferase 5 (PRMT5; IC50 = 22 nM). It is selective for PRMT5 over a panel of methyltransferases, including PRMT4, -6, and -7 at 1 μM. It reduces symmetric demethylation of SmBB'' in MCF-7 cells (IC50 = 25 nM) and inhibits proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM). LLY-283 (20 mg/kg) inhibits tumor growth in an A375 mouse xenograft model. It also disrupts alternative splicing events in, and inhibits proliferation and self-renewal of, patient-derived glioblastoma stem cells and increases survival in an orthotopic patient-derived xenograft (PDX) mouse model. See the Structural Genomics Consortium (SGC) website for more information. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|